RT Journal Article
T1 Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.
A1 Nguyen, Ai-Lan
A1 Havrdova, Eva Kubala
A1 Horakova, Dana
A1 Izquierdo, Guillermo
A1 Kalincik, Tomas
A1 van der Walt, Anneke
A1 Terzi, Murat
A1 Alroughani, Raed
A1 Duquette, Pierre
A1 Girard, Marc
A1 Prat, Alexandre
A1 Boz, Cavit
A1 Sola, Patrizia
A1 Ferraro, Diana
A1 Lugaresi, Alessandra
A1 Lechner-Scott, Jeannette
A1 Barnett, Michael
A1 Grand'Maison, Francois
A1 Grammond, Pierre
A1 Ramo-Tello, Cristina
A1 Turkoglu, Recai
A1 McCombe, Pamela
A1 Pucci, Eugenio
A1 Trojano, Maria
A1 Granella, Franco
A1 Spitaleri, Daniele
A1 Van Pesch, Vincent
A1 Soysal, Aysun
A1 Oreja-Guevara, Celia
A1 Verheul, Freek
A1 Vucic, Steve
A1 Hodgkinson, Suzanne
A1 Slee, Mark
A1 Ampapa, Radek
A1 Prevost, Julie
A1 Menoyo, Jose Luis Sanchez
A1 Skibina, Olga
A1 Solaro, Claudio
A1 Olascoaga, Javier
A1 Shaw, Cameron
A1 Madsen, Klaus Gregaard
A1 Naidoo, Kerisha
A1 Hyde, Robert
A1 Butzkueven, Helmut
A1 Jokubaitis, Vilija
A1 MSBase Study Group, 
K1 Incidence
K1 Multiple sclerosis
K1 Outcomes
K1 Pregnancy
K1 Therapy
AB Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RRMS) may be increasing. To retrospectively determine incidence of pregnancy, DMT exposure and pregnancy outcomes in women with RRMS. We identified all women with RRMS aged 15-45 years in the MSBase Registry between 2005-2016. Annualised pregnancy incidence rates were calculated using Poisson regression models. DMT exposures and pregnancy outcomes were assessed. Of 9,098 women meeting inclusion criteria, 1,178 (13%) women recorded 1,521 pregnancies. The annualised incidence rate of pregnancy was 0.042 (95% CI 0.040, 0.045). A total of 635 (42%) reported pregnancies were conceived on DMT, increasing from 27% in 2006 to 62% in 2016. The median duration of DMT exposure during pregnancy was 30 days (IQR: 9, 50). There were a higher number of induced abortions on FDA pregnancy class C/D drugs compared with pregnancy class B and no DMT (p = 0.010); but no differences in spontaneous abortions, term or preterm births. We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.
YR 2019
FD 2019-01-03
LK http://hdl.handle.net/10668/13395
UL http://hdl.handle.net/10668/13395
LA en
DS RISalud
RD Apr 10, 2025